ஆரம்ப நுழைவு ப்ரோக்ர்யாம் இல் யூரோப் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆரம்ப நுழைவு ப்ரோக்ர்யாம் இல் யூரோப். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆரம்ப நுழைவு ப்ரோக்ர்யாம் இல் யூரோப் Today - Breaking & Trending Today

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma
News provided by
Share this article
STOCKHOLM, March 8, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO
), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that it strengthens the leadership of the European operations by appointing Andrea Passalacqua as General Manager in Europe, and Pamela Bacon as Head of Medical Affairs Europe. The Company also announced that it opens an Early Access Program across Europe to address the significant need of new treatment alternatives in multiple myeloma. As previously announced, Oncopeptides will also seek a Conditional Marketing Authorization of melphalan flufenamide in triple class refractory multiple myeloma, during second quarter of 2021. ....

United States , Paula Boultbee , Andrea Passalacqua , Martyj Duvall , Rolf Gulliksen , Linda Holmstr , Oncopeptides Inc , Global Head Of Corporate Communications , Early Access Program , Global Head Of Medical Affairs , Leadership Team Of Oncopeptides , Head Of Medical Affairs In Europe , Early Access Program In Europe , European Medicines Agency , Access Program , Nasdaq Stockholm , General Manager , Pamela Bacon , Medical Affairs , Conditional Marketing Authorization , Chief Executive Officer , Leadership Team , Key Opinion Leaders , Clinical Oncology , Expanded Access Program , Sofia Heigis ,

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Paula Boultbee , Andrea Passalacqua , Martyj Duvall , Rolf Gulliksen , Linda Holmstr , Oncopeptides Inc , Global Head Of Corporate Communications , Early Access Program , Global Head Of Medical Affairs , Leadership Team Of Oncopeptides , Head Of Medical Affairs In Europe , Early Access Program In Europe , European Medicines Agency , Access Program , Nasdaq Stockholm , General Manager , Pamela Bacon , Medical Affairs , Conditional Marketing Authorization , Chief Executive Officer , Leadership Team , Key Opinion Leaders , Clinical Oncology , Expanded Access Program , Sofia Heigis ,

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Paula Boultbee , Andrea Passalacqua , Martyj Duvall , Rolf Gulliksen , Linda Holmstr , Oncopeptides Inc , Global Head Of Corporate Communications , Early Access Program , Global Head Of Medical Affairs , Leadership Team Of Oncopeptides , Head Of Medical Affairs In Europe , Early Access Program In Europe , European Medicines Agency , Access Program , Nasdaq Stockholm , General Manager , Pamela Bacon , Medical Affairs , Conditional Marketing Authorization , Chief Executive Officer , Leadership Team , Key Opinion Leaders , Clinical Oncology , Expanded Access Program , Sofia Heigis ,

European Medicines Agency Accepts GBT's Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease

Published: Jan 27, 2021
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation of GBT’s Marketing Authorization Application (MAA) for Oxbryta
® (voxelotor) tablets and started its standard review process. GBT is seeking full marketing approval from the EMA for Oxbryta to treat hemolytic anemia in patients with sickle cell disease (SCD) who are 12 years of age and older.
A first-in-class oral, once-daily therapy, Oxbryta directly inhibits hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD. The sickling process causes hemolytic anemia (low hemoglobin due to red blood cell destruction) and blockages in capillaries and small blood vessels, which impede the flow of blood and oxygen throughout the body. The diminished oxygen delivery to tissues and organs can lead to life-thr ....

United States , Steven Immergut , Courtney Roberts , Centers For Disease , European Commission , Drug Administration , Global Blood Therapeutics Inc , Exchange Commission , American Society Of Hematology , Early Access Program In Europe , Securities Exchange , European Medicines Agency , Blood Institute , National Heart , Blood Therapeutics , Authorization Application , Hemoglobin Oxygen Affinity Modulation , Inhibit Hbs Polymerization , American Society , Annual Meeting , Oxbryta Priority Medicines , Early Access Program , South Asian , Southern European , Middle Eastern , Oxbryta Breakthrough Therapy ,